<div id="readability-page-1"><div> ** Shares of CSPC Pharmaceutical Group Ltd rise 5.2% to HK$7.95, their biggest intraday pct gain since September 1** Stock hits its highest point since November 17 ** CSPC said a double-stranded small interfering RNA (siRNA) drug, SYH2061 Injection - a Class 1 new chemical drug developed by the company, has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States ** Co says the product, which is an siRNA drug that achieves liver-targeted delivery, also obtained approval from China's National Medical Products Administration in October 2025 to conduct clinical trials in China ** YTD, stock up 65.7%, Hang Seng Biotech Index (.HSBIO) up 80.2%</div></div>

01093

CSPC Pharmaceutical Group Ltd's shares rose 5.2% to HK$7.95 after their siRNA drug, SYH2061 Injection, received FDA approval for clinical trials in the US. The drug also received approval in China in October 2025. The stock has increased 65.7% YTD, while the Hang Seng Biotech Index is up 80.2%.

CSPC Pharma rises as product obtains clinical trial approval in US